Background-The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT 1 R) and cysteinyl leukotriene 2 receptor (CysLT 2 R). However, the distinct contribution of CysLT 2 R to the vascular actions of CysLTs has not been addressed. Methods and Results-We generated an endothelial cell-specific human CysLT 2 R (EC-hCysLT 2 R) transgenic (TG) mouse model using the Tie2 promoter/enhancer. Strong expression of hCysLT 2 R in TG lung and endothelial cells, detected by real-time polymerase chain reaction, markedly enhanced CysLT-stimulated intracellular calcium mobilization compared with endogenous expression in cells from nontransgenic mice. The permeability response to exogenous LTC 4 and to endogenous CysLTs evoked by passive cutaneous anaphylaxis was augmented in TG mice. The rapid, systemic pressor response to intravenous LTC 4 was also diminished in TG mice coincidentally with augmented production of nitric oxide. Conclusions-The development of EC-hCysLT 2 R mice has permitted detection of distinct vascular effects of CysLTs, which can be mediated via the CysLT 2 R in vivo. 
C ysteinyl leukotrienes (CysLTs), leukotriene C 4 (LTC 4 ), leukotriene D 4 (LTD 4 ), and leukotriene E 4 (LTE 4 ), have been well established as inflammatory mediators since their discovery 25 years ago. 1 Their major effects include smooth muscle constriction, enhancement of vascular permeability, promotion of mucus secretion, and eosinophil recruitment, 2 all characteristic signs of allergic asthma. CysLTs mediate their actions via 2 receptors: the cysteinyl leukotriene 1 receptor (CysLT 1 R) and the cysteinyl leukotriene 2 receptor (CysLT 2 R). 3, 4 Selective CysLT 1 R antagonists have been developed that block the majority of CysLT effects in asthmatic airways and are commonly used in the treatment of asthma and allergic rhinitis. 5, 6 The absence of CysLT 2 R-selective antagonists and appropriate animal models has contributed to our lack of understanding of the functional roles of this receptor subtype.
Both human and mouse CysLT 1 R 7-10 and CysLT 2 R 11-15 genes were cloned in recent years and transiently expressed in heterologous systems. They belong to a subfamily of G protein-coupled receptors with 30 to 40% homology between the receptor subtypes. The rank order agonist affinities are as follows: LTD 4 ϾLTC 4 ϾLTE 4 for CysLT 1 R and LTC 4 ϭ LTD 4 ϾLTE 4 for CysLT 2 R. CysLT 1 R couples to G q/11 and/or G i/o in various cell types, whereas CysLT 2 R couples to G q and activation elicits intracellular calcium mobilization. CysLT 1 R is expressed primarily in bronchial smooth muscle cells; peripheral blood leukocytes, including eosinophils and monocytes; and mast cells, as reflected by mRNA and immunoreactivity analyses. CysLT 2 R, surprisingly, exhibits high expression in heart and coronary vessels and a diffuse pattern in brain, with expression also detected in adrenal gland, eosinophils, monocytes, and mast cells. The contrasting patterns of receptor expression imply distinct functions for CysLT receptors.
Evidence for at least 2 CysLT receptor subtypes in pulmonary vasculature, in both smooth muscle cells and endothelium, has been presented on the basis of pharmacological studies. 16, 17 Cultured human coronary endothelial cells (ECs) 18 and human umbilical vein ECs express CysLT 2 R but lack CysLT 1 R. 19, 20 CysLTs can induce surface expression of P-selectin in human umbilical vein ECs 21, 22 that is not blocked by CysLT 1 R antagonists. 22 Moreover, CysLT receptors on human pulmonary vessel endothelium mediate relaxation that is not modified by CysLT 1 R antagonists. 16 These data are consistent with the existence of a functionally important CysLT 2 R on ECs. Both CysLT 1 R-knockout mice 23 and mice in which the human CysLT 1 R is overexpressed in airway and vascular smooth muscle 24 have been generated.
However, no models are extant in which expression of CysLT 2 R has been manipulated. We have generated mice in which the human CysLT 2 R is overexpressed in ECs and report effects on endothelial integrity and blood pressure (BP) regulation mediated by this receptor subtype in vivo.
Methods

Generation of EC-Specific Human CysLT 2 R Transgenic Mice
EC-specific expression was achieved via the Tie2 promoter/enhancer (gift from Dr. T. Sato, University of Texas Southwestern Medical Center, Dallas, Tex). A 2.1-kb Tie2 promoter fragment was subcloned into pBluescript SKϩ flanked by the hCysLT 2 R coding region, SV40 polyadenylation signal sequence, and the 10.1-kb complete Tie2 enhancer sequence. A 13.5-kb fragment was released from the vector by SalI digestion, purified by Elutip-D columns (Schleicher & Schuell BioScience), and microinjected into the pronuclei of fertilized zygotes from C57BL/6ϫSJL F1 mice (obtained from Jackson Laboratory, Bar Harbor, Me). Injections were performed at the University of Pennsylvania Transgenic and Chimeric Mouse Facility. Founders and their hemizygous transgenepositive progeny were genotyped by polymerase chain reaction (PCR) using hCysLT 2 R specific primers (forward, 5Ј-TGCTC-CTGGACAGTGGCTCTGAG-3Ј; reverse, 5Ј-GCTCCTTATAC-TCTTGTTTCCTTTCTCAACC-3Ј) or by Southern blot analysis with a [
32 P]-labeled hCysLT 2 R-specific probe and were backcrossed with C57BL/6 mice. Littermates of a common genetic background between the ages of 10 to 14 weeks were used for all in vivo studies under anesthesia (ketamine 100 mg/kg, acepromazine 3 mg/kg). Animal protocols were approved by the Animal Care and Use Committee at the University of Pennsylvania.
Transgene Integration Detection by Inverse PCR
Csp6I cut genomic DNA (150 ng) was self-circularized with T4 ligase (2 Weiss units) at 16°C for 16 hours and used for first-round PCR with forward ACACGTCTAACCTCAGCATCTGG and reverse ACTATGAAGCCAGGAGTGGTGC primers within the Tie2 promoter. The mixture (1:1000) was subjected to nested PCR using AGGAGGGCGGGTGGTTG and GGGAATGGATTAAGAGT-TCAAGGTC primers. The nested PCR products were gel-purified, cloned into pCR2.1-TOPO vector, and sequenced.
PCR Analyses
For reverse transcription (RT)-PCR, total RNA (2 g) prepared with RNeasy Mini Kit (Qiagen), treated with DNaseI, was reverse transcribed with the SuperScript First-Strand Synthesis System (Invitrogen), and PCR was performed with the hCysLT 2 R primers mentioned above. For real-time assays, cDNA was prepared with TaqMan transcription reagents, and PCR reactions were prepared in SYBR Green PCR Master Mix. DNA targets were amplified and analyzed with an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Mouse GAPDH (CATGGCCTTCCGTGT-TCCTA; ATGCCTGCTTCACCACCTTCT), mouse CysLT 1 R (GCAAGTGGCTCTTTGGTGACT; AAGATGCTACAATAGAG-GTTAACGTACAA), mouse CysLT 2 R (CATGTGTATGCCTGAT-GTCTACCA; CATTTGCCGTACCCAGTCTCA), and human CysLT 2 R (TGCAACCATCCATCTCCGTAT; TGTGCAGTTCCT-GCTGTTGTTAT) were amplified. The mCysLT 1 R, mCysLT 2 R, and hCysLT 2 R mRNA levels were normalized to GAPDH. No significant differences in GAPDH levels were detected between different samples when the same amount of total RNA was used (data not shown).
Isolation of Murine Primary Lung ECs
Lung ECs (LECs) were prepared from 4-to 8-week-old mice. 25 Immunofluorescence analyses were performed as described previously, 26 using rabbit anti-human CD 62P polyclonal antibody (1 g/ mL; Becton Dickinson). The uptake of acetylated LDL-DiI complex (DiI-Ac-LDL, Molecular Probes) was used to characterize the ECs.
Isolation of Murine Primary Aortic Smooth Muscle Cells
Mouse aorta strips with the intima scraped off were cultured under a glass cover slide in DMEM/F-12 medium containing 20% FBS, 0.5% penicillin-streptomycin, and 1% L-glutamine. The cover slide and aorta were removed after 10 days, and smooth muscle cells were characterized by anti-␣-smooth muscle actin-FITC conjugate (Sigma) staining.
Intracellular Calcium Mobilization
LECs (passage 5) from transgenic (TG) and nontransgenic (NTG) mice were seeded in a 384-well clear black plate at a density of 10 000 cells/well in a volume of 25 L and allowed to adhere overnight. Cells were loaded with 25 L Calcium 3 No Wash Dye (Molecular Devices) supplemented with probenecid and incubated at 37°C, 5% CO 2 , for 1 hour, followed by LT/vehicle addition. Calcium fluorescent signals were monitored for 5 minutes by a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices) and corrected with background readings from adjacent wells.
Vascular Ear Permeability Assay
Anesthetized mice received 200 L of 2% Evans blue dye in PBS injected via the tail vein. Immediately thereafter, the right ear was injected intradermally with LTC 4 (Cayman Chemical Co) in 10 L saline containing either 0.1% or 0.5% ethanol vehicle, whereas the left ear was injected with vehicle. Animals were euthanized after 15 minutes by CO 2 inhalation. A 6-mm ear biopsy (Acu-Punch, Acuderm Inc) was soaked in formamide (750 L) overnight at 55°C, and extracted Evans blue dye was measured by absorbance at 610 nm with a Beckman DU-600 spectrophotometer.
Passive Cutaneous Anaphylaxis Assay
Anesthetized mice received intradermal injections of 40 ng monoclonal anti-dinitrophenyl IgE in 20 L saline in the right ear and 20 L saline in the left ear. After 24 hours, animals were administered dinitrophenyl-human serum albumin (200 g) in 200 L 1% Evans blue dye (in PBS) via the tail vein, and 30 minutes later, ear tissues were analyzed for dye leakage as described above.
Mean Arterial BP Measurements
The right internal jugular vein and left carotid artery of anesthetized mice were cannulated with PE-10 tubing. The arterial catheter was connected to a Capto SP844 pressure transducer, and BP was monitored continuously with a PowerLab/8SP system. Mice were injected via the right internal jugular vein with LTC 4 (0.3, 1, or 3 g/kg in 4 mL/kg saline). The same volume of saline was injected before LTC 4 administration to exclude volume-mediated BP changes.
Measurement of Plasma Nitric Oxide Metabolites
Mice were injected with 1 g/kg of LTC 4 (0.25 g/mL in saline) via the tail vein, and blood (100 L) was drawn from the saphenous vein with a Microvette 200 LH (Sarstedt) at times 0, 5 minutes, and 30 minutes after LTC 4 injection. Plasma total nitrate/nitrite was measured with a fluorometric assay kit (Cayman Chemical Co) according to the manufacturer's instructions.
Statistics
Analyses were performed by Student's t test or 1-way ANOVA using Graph Pad Prism software. A value of PϽ0.05 was considered significant. Data are presented as meanϮSEM.
Results
Identification of EC-hCysLT 2 R TG Mice
The Tie2 promoter and complete enhancer 27 were used to achieve EC-specific expression of hCysLT 2 R ( Figure 1A ).
Four founder mice (mice 3, 4, 10, and 15) were identified from a total of 21 screened offspring. One female died during delivery, and 2 other founder lines were excluded from additional studies because of mosaicism and low-level hCysLT 2 R expression, similar to endogenous mCysLT 2 R mRNA levels. Mice from founder line 4 exhibited high-level hCysLT 2 R expression (see below), and hemizygous mice from this line were used for all subsequent studies. Transgene copy number analysis indicated Ϸ7 copies integrated into the mouse genome in a head-to-tail orientation ( Figure 1B ) at chromosome 6 B1 region (34 557 689 bp) ( Figure 1C ) within a gene-sparse region. The closest gene, bisphosphoglycerate mutase, is 109 kb distant at proximal location 34 419 267 to 34 448 521 bp. The integration of the transgene did not physically disrupt any genes and would not be expected to exert any nonspecific integration effects.
hCysLT 2 R Expression in TG Mice
Expression of hCysLT 2 R mRNA in lung tissue of TG mice was subjected to real-time PCR analyses and found to be 200-fold higher than endogenous mCysLT 2 R levels. Expression of mCysLT 2 R in TG mice did not change relative to NTG mice (Figure 2A ). Northern blot analysis detected a strong 2-kb band transcript in TG but not NTG lung ( Figure  2B ). hCysLT 2 R mRNA in TG liver was not detected but may have been masked by the abundance of hepatocyte mRNA.
LECs (99% positive for the endothelial cell-specific marker P-selectin staining and DiI-Ac-LDL uptake) and aortic smooth muscle cells (ASMCs; Ͼ90% positive for ␣-actin) were cultured and used to determine the specificity of transgene expression by RT-PCR. hCysLT 2 R expression was detected as a 532-bp band in TG lung, LECs, and aorta but not in ASMCs ( Figure 2C ). However, expression in cultured LECs was diminished compared with lung tissue (Figure 2B ), possibly because of gene silencing by in vitro culture.
CysLTs Elicit Robust Intracellular Calcium Mobilization Responses in TG LECs
We determined whether intracellular calcium mobilization induced by CysLTs could be augmented in TG LECs through G q to evaluate the functionality of EC-hCysLT 2 R. Whereas LECs from NTG mice showed a minimal response to 1 mol/L LTC 4 and LTD 4 , TG LECs responded to both agonists with a prominent calcium signal peak. Cells of both genotypes did not respond to LTE 4 or LTB 4 ( Figure 3A) . Figure 3B 
EC-hCysLT 2 R TG Mice Exhibit Enhanced Vascular Permeability in Response to CysLTs
We investigated the role of CysLT 2 R in mediating vascular permeability changes as measured by Evans blue dye extravasation. Exogenous LTC 4 administration elicited an increase in vascular permeability in both NTG and TG mice within 15 minutes. Whereas the permeability change in NTG mice was small, the response in TG mice was potentiated by Ϸ90% (nϭ7 to 8; PϽ0.05) and Ϸ5-fold (nϭ11 to 12; PϽ0.0001) in response to 1 and 5 ng LTC 4 , respectively ( Figure 4A ). Dye extravasation caused by CysLTs produced endogenously by activated mast cells in passive cutaneous anaphylaxis was augmented by Ϸ80% (nϭ7 to 9; PϽ0.05) in TG mice compared with NTG littermates 30 minutes after antigen challenge ( Figure 4B ). Expression of hCysLT 2 R in the TG ear vascular bed was verified by real-time PCR ( Figure 4C ). Neither mCysLT 1 R nor mCysLT 2 R endogenous expression levels were changed in TG ears. These results indicate that CysLT 2 R can mediate CysLT-induced permeability changes.
LTC 4 -Induced Systemic Pressor Effect in NTG Mice Is Diminished in EC-hCysLT 2 R TG Mice
Mean arterial pressure (MAP) was monitored continuously in anesthetized mice. Baseline MAP did not differ between NTG and TG mice (data not shown). LTC 4 administered systemically caused an immediate rise in MAP that gradually fell to baseline within 3 to 15 minutes in NTG mice ( Figure  5A , top, and B). Average MAP increased 15%, 20%, and 23% on 0.3 g/kg, 1 g/kg, and 3 g/kg LTC 4 infusion, respectively. Although the overall BP response followed a similar time course in TG littermates, MAP changed significantly compared with the NTG controls (ϩ7%, nϭ5 to 6, PϽ0.05; Ϫ8%, nϭ6 to 8, PϽ0.005; and ϩ4%, nϭ5, PϽ0.001) at the respective LTC 4 infusion concentrations ( Figure 5A , bottom, and B).
Plasma NO Metabolites Are Increased in EC-hCysLT 2 R TG Mice
The response of plasma NO metabolites to LTC 4 1 g/kg systemic infusion was evaluated. Baseline levels did not differ between NTG and TG mice (data not shown). Total nitrate/nitrite increased marginally after LTC 4 injection and remained stable at this level for at least 30 minutes in NTG mice. The increase in these metabolites was significantly potentiated in plasma obtained from TG mice (nϭ8; PϽ0.05; Figure 6 ).
Discussion
We have established the first TG animal model designed to study CysLT 2 R function. We confirmed increased endothelial expression of the hCysLT 2 R transcript in TG mice and the functionality of this receptor by measuring CysLT-induced calcium mobilization. The only available pharmacological antagonist for CysLT 2 R, BAY u9773, also weakly antagonizes the CysLT 1 R and acts as a partial agonist at the CysLT 2 R. 28 These properties have precluded its use in defining in vivo CysLT 2 R functions.
Increased vascular permeability is a feature of inflammation. CysLTs induce a rapid dose-dependent plasma extravasation from postcapillary venules, 1000 times more potent than histamine, 29 which can be inhibited by CysLT 1 R antagonists. 30 Moreover, CysLT 1 R-deficient mice display decreased plasma leakage in passive cutaneous anaphylaxis, 23 indicating that CysLT 1 R is the major mediator of CysLT action in this process. However, BAY u9773 is more efficient than a CysLT 1 R antagonist in reducing edema in a guinea pig brain perfusion assay in vitro, 31 raising the possibility of a contribution from the CysLT 2 R. The results of our studies in EC-hCysLT 2 R mice are consistent with this hypothesis, because permeability in the ear vasculature was augmented in TG mice. Indeed, this response may be dominantly transduced via the CysLT 2 R in heart and brain, where this receptor subtype predominates. Histamine and many other G proteincoupled receptors that couple to G q induce the loss of endothelial barrier function through a calcium-dependent pathway, leading to junctional disassembly, 32 a pathway that may be in operation in EC-hCysLT 2 R mice. , ϫ40) and DiI-Ac-LDL uptake (c, ϫ20); primary ASMCs were stained for ␣-actin (d, ϫ40) and also P-selectin (b, ϫ40) as a negative control for ECs. Nuclei were stained blue with DAPI. hCysLT 2 R expression was detected by RT-PCR. RTϪ, controls without addition of reverse transcriptase were used to show no PCR contamination from multicopied transgene in genomic DNA. Presence of aorta (intima and media only) transcript and absence of ASMC transcript indicate EC-restricted expression. ASMC genomic DNA (gDNA) control was used to show presence of transgene.
CysLTs evoke contradictory effects on vascular tone, depending on the species and the experimental preparations, 33 with both endothelium-and smooth muscle-dependent effects. Although the endothelium usually contributes to CysLT-mediated relaxation and smooth muscle to direct contractile responses, the resolution of these actions as a change in BP has been difficult to predict. For instance, intravenous injection of LTD 4 exerts a pressor effect in conscious rats, 34 whereas both LTC 4 and LTD 4 decrease arterial pressure in anesthetized guinea pigs. However, high doses of the CysLTs paradoxically increase BP for a period of time, followed by transient hypotension in unanesthetized guinea pigs. 35 The effects of CysLTs on vascular tone and BP have not been examined previously in mice. We found that LTC 4 increased MAP in NTG mice in a dose-dependent manner. However, this pressor effect was significantly reduced or even paradoxically reversed (LTC 4 1 g/kg) in EC-hCysLT 2 R mice, substantiating an apparent relaxant role for endothelial CysLT 2 R in BP regulation during inflammation or anaphylaxis. The BP response in TG mice failed to reveal dose dependency, further suggesting the complex nature in CysLT-mediated vascular tone regulation. Wildtype mice express both CysLT 1 R and CysLT 2 R in cultured LECs and ASMCs at comparable levels (data not shown). Although Brink et al 36 summarized pharmacological characterization of CysLT receptors in different vascular preparations, the limitations of currently available pharmacological probes constrain predictions of receptor subtype-specific vascular responses to CysLTs in vivo.
Mechanisms for endothelium-mediated CysLT-generated vasodilation appear to involve NO and/or prostacyclin synthesis. NO release may be more important in human and porcine pulmonary veins 16, 37 and canine splanchnic vein, 38 whereas prostacyclin may be the major mediator for human pulmonary artery dilation. 17 Thus, CysLT receptors may couple to different signaling pathways in ECs in a vascular bed-specific manner, leading to decreased peripheral resis- tance and/or decreased venous return and cardiac output. We speculate that these pathways might account for the systemic hypotensive effect generated by overexpressed hCysLT 2 R on endothelium.
Our observation that NO metabolites increase marginally in NTG mice and to a much greater extent in EC-hCysLT 2 R mice in response to LTC 4 corroborates previous studies showing NO involvement in CysLT responses in various vascular preparations. Endothelial NO synthase activation is calcium dependent, 39 which is consistent with hCysLT 2 R function to elevate cellular calcium through G q . However, BP responses to LTC 4 were immediate and returned to baseline within 15 minutes, in contrast to NO metabolite levels in TG mice, which increased steadily over a 30-minute period.
Because NO and related nitrogen oxides interact with a large array of molecules and shuttle between tissues, plasma, and red blood cells, 40 the time needed for NO metabolites to "equilibrate" between different compartments in vivo might be longer than the effective duration of NO produced during LTC 4 stimulation. NO might also be formed in TG mice for purposes other than vascular tone regulation.
In summary, we demonstrate that EC-hCysLT 2 R mice have augmented vascular permeability and reduced pressor responses to CysLTs. This mouse model may mimic pathophysiological settings in which endothelial CysLT 2 R can be induced, for example, by cytokines. 19 Endothelial CysLT 2 R may exacerbate inflammation by increasing vascular permeability and possibly by recruiting more neutrophils through enhanced P-selectin expression. It may participate in severe hypotensive responses in life-threatening anaphylaxis. Moreover, augmented CysLT 2 R-dependent NO formation could interact with superoxide to form peroxynitrite in settings in which vascular inflammation coincides with increased oxidant stress, such as in atherosclerosis and ischemiareperfusion injury. 40 Manipulated expression of the CysLT 2 R in vivo is likely to reveal further the importance of this potential drug target in cardiovascular biology. 
